苯并二氧六环-6-甲酸甲酯 | 20197-75-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并二恶烷
• 中文名称: 苯并二氧六环-6-甲酸甲酯
• 中文别名: 2,3-二氢-1,4-苯并二噁英-6-羧酸甲酯；1,4-苯并二噁烷-6-甲酸甲酯
• 英文名称: 2,3-dihydro-benzo[1,4]dioxine-6-carboxylic acid methyl ester
• 英文别名: methyl 2,3-dihydrobenzo[b][1,4]dioxine-6-carboxylate；Methyl 2,3-dihydro-1,4-benzodioxine-6-carboxylate
• CAS: 20197-75-5
• 化学式: C₁₀H₁₀O₄
• mdl: MFCD01544907
• 分子量: 194.187
• InChiKey: GYUXWAIDEGEMEE-UHFFFAOYSA-N

物化性质

• 沸点：
  135-140 °C(Press: 1-2 Torr)
• 密度：
  1.242±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  44.8
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2932999099
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302
• 储存条件：
  室温且干燥

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2,3-Dihydro-1,4-benzodioxin-6-carboxylic acid methyl ester
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2,3-Dihydro-1,4-benzodioxin-6-carboxylic acid methyl ester
CAS number: 20197-75-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H10O4
Molecular weight: 194.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  苯并二氧六环-6-甲酸甲酯 在 sodium hydroxide 、 盐酸 作用下， 以 水 为溶剂， 反应 5.0h， 生成 2,3-二氢-1,4-苯并二噁烷-6-羧酸
  参考文献：
  名称：

  Synthesis, structure, and urease inhibitory activities of three binuclear copper(II) complexes with protocatechuic acid derivative

  摘要：

  Three Cu(II) complexes, [Cu-2(II)(L-1)(4)(L-2)(2)] (1), [Cu-2(II)(L-1)(4)(H2O)(2)]center dot HL (2), and [Cu-2(II)(L-1)(3)(L-3)(2)]ClO4 (3), with a ligand derived from protocatechuic acid (HL1= C9H8O4=2,3-dihydrobenzo[b][1,4]-dioxine-6-carboxylic acid, L-2= C7H9N=o-toluidine, L-3= C6H16N2=N, N-diethylethylenediamine) were synthesized and characterized by C, H, and N elemental analysis and single-crystal X-ray diffraction, which revealed that the three complexes have similar binuclear structures. Complexes 1 and 3 crystallized in triclinic space group P-1 and 2 in orthorhombic space group P2(1)2(1)2(1). The urease inhibitory activities of the three complexes were tested. All three complexes showed strong inhibitory activity against jack bean urease with an IC50 value of 6.8, 5.5, and 3.5 mu M compared with the acetohydroxamic acid (IC50 = 7.5 mu M), which was a positive control.

  DOI：

  10.1080/00958972.2014.910597
• 作为产物：
  描述：

  原儿茶酸 在 硫酸 、 potassium carbonate 作用下， 以 丙酮 为溶剂， 反应 32.0h， 生成 苯并二氧六环-6-甲酸甲酯
  参考文献：
  名称：

  具有1,4-苯并二恶烷部分的1,3,4-恶二唑的合成及其抗肿瘤活性

  摘要：

  已设计，合成并评估了一系列含有1,4-苯并二恶烷部分（7a – 7q）的1,3,4-恶二唑衍生物的抗肿瘤活性。已证明大多数合成的化合物具有有效的抗肿瘤活性和低毒性。其中，化合物7a对人脐静脉内皮细胞表现出最强的生物学活性，与阳性对照相当。凋亡和流式细胞仪（FCM）的结果表明，化合物7a通过抑制MetAP2途径诱导细胞凋亡。进行分子对接以将化合物7a定位于MetAP2结合位点，以探索潜在的靶标。

  DOI：

  10.1016/j.bmcl.2013.03.068

文献信息

• MEDICINAL COMPOSITIONS
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1402900A1

  公开（公告）日：2004-03-31

  The present invention relates to an agent for the prophylaxis or treatment of pain, an agent for suppressing activation of osteoclast, and an inhibitor of osteoclast formation, which contains a p38 MAP kinase inhibitor and/or a TNF-α production inhibitor.

  本发明涉及一种用于预防或治疗疼痛的药剂，一种用于抑制破骨细胞活化的药剂，以及一种包含p38 MAP激酶抑制剂和/或TNF-α产生抑制剂的破骨细胞形成抑制剂。
• CONCOMITANT DRUGS
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1354603A1

  公开（公告）日：2003-10-22

  The present invention relates to a pharmaceutical agent containing one or more kinds of a p38 MAP kinase inhibitor and/or a TNF-α production inhibitor and one or more kinds of drugs selected from the group consisting of (1) a non-steroidal antiinflammatory drug, (2) a disease-modifying anti-rheumatic drug, (3) an anti-cytokine drug, (4) an immunomodulator, (5) a steroid and (6) a c-Jun N-terminal kinase inhibitor in combination. This combination agent is useful as a prophylactic or therapeutic agent of the diseases such as rheumatism, arthritis and the like, and other diseases.

  本发明涉及一种含有一种或多种p38 MAP激酶抑制剂和/或TNF-α产生抑制剂以及从（1）非甾体抗炎药、（2）疾病修饰性抗风湿药、（3）抗细胞因子药物、（4）免疫调节剂、（5）类固醇和（6）c-Jun N末端激酶抑制剂中选择的一种或多种药物的药物制剂。这种组合药剂可用作预防或治疗风湿病、关节炎等疾病以及其他疾病的药物。
• 作为PI3K/mTOR抑制剂的三环类化合物，其 制备方法和用途
  申请人：上海汇伦生命科技有限公司

  公开号：CN104557955B

  公开（公告）日：2017-05-03

  本发明公开的作为PI3K/mTOR抑制剂的三环类化合物，为具有以下通式（I）的化合物。其中，Ar选自芳基或杂芳基；X、Y、Z分别独立选自O、CR2R3、NR4；Q选自O、CR2R3、NR4或不存在；R1为C1至C6烷基；n选自0‑4的整数；当n≥2时，可由两个R1与吗啉环组合为并环、桥环或螺环；R2，R3选自氢、C1至C6烷基；R4选自氢、C1至C6烷基、C3至C7环烷基、杂环基、酰基、磺酰基。本发明还公开了通式（I）化合物的制备方法，其药物组合物和用途。
• 含咪唑稠合三环类化合物及其应用
  申请人：广州必贝特医药技术有限公司

  公开号：CN107383024B

  公开（公告）日：2018-06-08

  本发明公开了具有式(I)所示结构的含咪唑稠合三环类化合物或者其药学上可接受的盐或者其立体异构体或者其前药分子。该类化合物具有调节IDO1活性的作用，这类化合物通过阻断免疫检查点IDO1，可以增强T细胞激活，用于治疗IDO1介导的免疫抑制，从而能够成为治疗恶性肿瘤的有效药物。与检查点蛋白的抗体药物或其他抗癌药物合用，可以增强抗癌效果。同时也有潜力有效治疗与IDO1异常有关的免疫抑制性疾病，有较大的应用价值。
• Synthesis and antitumor activity of 1,2,4-triazoles having 1,4-benzodioxan fragment as a novel class of potent methionine aminopeptidase type II inhibitors
  作者：Ya-Ping Hou、Juan Sun、Zhong-Hua Pang、Peng-Cheng Lv、Dong-Dong Li、Li Yan、Hong-Jia Zhang、Emily Xi Zheng、Jing Zhao、Hai-Liang Zhu

  DOI：10.1016/j.bmc.2011.08.063

  日期：2011.10

  A series of 1,2,4-triazole derivatives containing 1,4-benzodioxan (5a–5q) have been designed, synthesized, structurally determined, and their biological activities were evaluated as potential MetAP2 inhibitors. All the synthesized compounds were first reported. Among the compounds, compound 5k showed the most potent biological activity against HEPG2 cancer cell line (IC50 = 0.81 μM for HEPG2 and IC50 = 0

  已设计，合成，结构确定了一系列含有1,4-苯并二恶烷（5a - 5q）的1,2,4-三唑衍生物，并将它们的生物活性作为潜在的MetAP2抑制剂进行了评估。所有合成的化合物都首先被报道。在化合物，化合物5K显示针对HEPG2癌细胞系的最有效的生物活性（IC 50  = 0.81μM为HEPG2和IC 50  = 0.93μM为的MetAP2），这是与阳性对照。通过将化合物5k置于MetAP2结构活性位点进行对接模拟，以探索可能的结合模型。凋亡和Western-blot检测结果表明该化合物5k对HEPG2癌细胞系具有良好的抗肿瘤活性。因此，在肿瘤生长抑制中具有有效抑制活性的化合物5k可能是针对HEPG2癌细胞的潜在抗肿瘤剂。